STOCK TITAN

If You Invested in uniQure N.V. (QURE)

Healthcare · Biotechnology · NASDAQ
Looking for the current price? See the QURE quote & overview
$1,000 invested 1 Year Ago
$699
-30.1% price return
-30.1% with dividends reinvested
Bought on Nov 18, 2025 at $29.71 split-adjusted
$1,000 invested 5 Years Ago
$710
-29.0% price return -6.6% CAGR
-29.0% with dividends reinvested
Bought on Nov 18, 2021 at $29.25 split-adjusted

What $1,000 or $10,000 in QURE Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Nov 19, 2015
$1,000 $699 -30% $710 -29% $2,919 +192% $1,146 +15%
$10,000 $6,994 -30% $7,104 -29% $29,185 +192% $11,455 +15%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-17. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for QURE

$1,000 Investment Over Time

QURE vs S&P 500

Year-by-Year Returns

QURE annual performance
Year Start Price End Price Annual Return Cumulative
2015Nov 19 to Dec 31 $18.14 $16.54 -8.8% -8.8%
2016 $16.54 $5.60 -66.1% -69.1%
2017 $5.60 $19.59 +249.8% +8.0%
2018 $19.59 $28.82 +47.1% +58.9%
2019 $28.82 $71.66 +148.6% +295.0%
2020 $71.66 $36.13 -49.6% +99.2%
2021 $36.13 $20.74 -42.6% +14.3%
2022 $20.74 $22.67 +9.3% +25.0%
2023 $22.67 $6.77 -70.1% -62.7%
2024 $6.77 $17.66 +160.9% -2.6%
2025 $17.66 $23.93 +35.5% +31.9%
2026Dec 31, 2025 to Nov 17 $23.93 $20.78 -13.2% +14.6%

About uniQure N.V.

Healthcare · NASDAQ

uniQure N.V. (NASDAQ: QURE) is a biopharmaceutical company focused on gene therapy for patients with severe medical needs. According to the company’s public statements, uniQure describes itself as "delivering on the promise of gene therapy – single treatments with potentially curative results." It is classified in pharmaceutical preparation manufacturing within the broader manufacturing sector and is incorporated in the Netherlands, with its ordinary shares listed on the Nasdaq Global Select Market under the symbol QURE.

Business focus and therapeutic areas

uniQure’s strategy centers on developing proprietary gene therapies that aim to address serious, often life‑threatening diseases. The company reports that the approvals of its gene therapy for hemophilia B represent a major milestone in genomic medicine and introduce a new treatment approach for people living with this bleeding disorder. The multi‑year clinical development of HEMGENIX (etranacogene dezaparvovec‑drlb), a one‑time gene therapy for adults with hemophilia B, was led by uniQure before commercialization rights were licensed to CSL.

Beyond hemophilia B, uniQure states that it is advancing a pipeline of gene therapies for:

  • Huntington’s disease (HD) through its investigational program AMT‑130
  • Refractory mesial temporal lobe epilepsy (also described as refractory temporal lobe epilepsy) via AMT‑260
  • Fabry disease through AMT‑191
  • SOD1 amyotrophic lateral sclerosis (ALS) through AMT‑162
  • Other severe diseases referenced in its public communications

Key programs and clinical development

A core element of uniQure’s business is the development of AMT‑130 for Huntington’s disease. The company has conducted multi‑center, dose‑escalating Phase I/II clinical trials in the United States and Europe, including randomized and open‑label cohorts. In these studies, patients with early manifest Huntington’s disease received a single administration of AMT‑130 delivered directly into the striatum using MRI‑guided, convection‑enhanced stereotactic neurosurgical procedures. Long‑term follow‑up of treated patients extends for several years.

According to uniQure’s reported topline data from its pivotal Phase I/II program, high‑dose AMT‑130 met the primary endpoint of statistically significant slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months, when compared to a propensity score‑matched external control derived from the Enroll‑HD natural history data set. A key secondary endpoint, Total Functional Capacity (TFC), also showed statistically significant slowing of disease progression versus the external control. The company has additionally reported favorable trends in other motor and cognitive measures and a mean reduction in cerebrospinal neurofilament light protein, a biomarker associated with neurodegeneration.

uniQure has disclosed that AMT‑130 was generally well‑tolerated in its Phase I/II studies, with a manageable safety profile across doses and no new drug‑related serious adverse events observed after a specified cutoff date. The most common adverse events were related to the administration procedure and were reported to have resolved.

Regulatory interactions and designations

Regulatory engagement is a central component of uniQure’s business model. The company has reported multiple interactions with the U.S. Food and Drug Administration (FDA) regarding AMT‑130, including Type B and pre‑Biologics License Application (BLA) meetings. In its public disclosures, uniQure states that the FDA granted Breakthrough Therapy designation to AMT‑130 based on Phase I/II data compared to external controls and Regenerative Medicine Advanced Therapy (RMAT) designation in a prior period.

Following a pre‑BLA meeting, uniQure announced that it believes the FDA currently no longer agrees that the existing Phase I/II data, in comparison to an external control, may be adequate to provide the primary evidence in support of a BLA submission for AMT‑130. As a result, the company has indicated that the timing of its BLA submission is unclear and that it plans further discussions with the FDA, including a scheduled Type A meeting to discuss the BLA data package and a potential accelerated approval pathway.

Pipeline beyond Huntington’s disease

In addition to AMT‑130, uniQure is advancing several other clinical‑stage programs, as described in its press releases and SEC filings:

  • AMT‑260 for refractory mesial temporal lobe epilepsy, where the company has reported enrollment of initial cohorts in a Phase I/IIa study and plans for additional data readouts.
  • AMT‑191 for Fabry disease, with initial safety and exploratory efficacy data showing increases in α‑Gal A activity and withdrawal from enzyme replacement therapy in early treated patients, alongside a manageable safety profile.
  • AMT‑162 for SOD1 ALS, where enrollment in a Phase I/II study was voluntarily paused following a dose‑limiting toxicity that resulted in a serious adverse event deemed related to AMT‑162; the company has stated it will continue to collect and evaluate data from treated patients.

These programs illustrate uniQure’s focus on neurological and metabolic disorders where gene therapy may offer a one‑time treatment approach.

Commercial and partnership aspects

For hemophilia B, uniQure led the multi‑year clinical development of HEMGENIX and then licensed global rights to CSL to commercialize the treatment. Public communications from CSL note that HEMGENIX is a one‑time gene therapy for adults with hemophilia B and that the therapy’s development was led by uniQure before the transition of trial sponsorship and commercialization rights. This collaboration provides an example of how uniQure can generate value from its gene therapy platforms through licensing and partnership structures.

Capital markets and financing

uniQure’s SEC filings describe a range of financing activities that support its research and development operations. The company has executed underwritten public offerings of ordinary shares and pre‑funded warrants, entered into an at‑the‑market equity program, and amended a senior secured term loan facility with Hercules Capital. These transactions are described as providing funds for commercialization readiness, potential commercial launch activities related to AMT‑130, development of other clinical candidates, business development initiatives, research projects, and general corporate purposes.

In its 8‑K filings, uniQure reports that its ordinary shares trade on the Nasdaq Global Select Market and that it has used shelf registration statements on Form S‑3 to facilitate offerings. The company has also disclosed the terms of its loan agreement amendments, including interest rates, maturity dates, and conditions for drawing additional tranches tied to capital raising and regulatory milestones for AMT‑130.

Regulatory disclosures and reporting

As a Nasdaq‑listed issuer, uniQure files current reports on Form 8‑K to disclose material events such as clinical data updates, regulatory interactions, financing agreements, and quarterly financial results. These filings provide investors with information on the company’s progress in gene therapy development, its regulatory strategy, and its financial position. Items commonly reported include results of operations and financial condition, entry into material definitive agreements, creation of direct financial obligations, and other events related to its clinical programs.

Role within gene therapy and pharmaceutical manufacturing

Within pharmaceutical preparation manufacturing, uniQure is positioned as a company focused on gene therapies that are intended to be administered once and to provide long‑term clinical benefit. Its work on hemophilia B, Huntington’s disease, refractory temporal lobe epilepsy, ALS, and Fabry disease, as described in its public communications, highlights a concentration on rare or severe conditions where conventional therapies can involve chronic treatment and significant disease burden.

Market Cap
$1.5B
Current Price
$20.78
EPS (FY2025)
-$3.46
Revenue (FY2025)
$16.1M
View full QURE overview

Frequently Asked Questions

uniQure N.V. investment returns

How much would $1,000 invested in uniQure N.V. be worth today?

If you invested $1,000 in uniQure N.V. (QURE) 10 years ago on 2016-11-18, your investment would be worth $2,919 as of 2026-11-17, a +191.9% price return without dividends, growing at a compounded rate of 11.3% per year (CAGR).

Has uniQure N.V. outperformed the S&P 500?

Over the past 10 years, QURE returned +191.9% compared to +235.2% for the S&P 500, underperforming the benchmark by 43.4 percentage points.

What is uniQure N.V.'s average annual return?

The compound annual growth rate (CAGR) of QURE’s share price over the past 10 years is 11.3%, without dividends. Individual years vary a great deal, and QURE’s best recent full year was 2017 (+249.8%) while the worst was 2023 (-70.1%).

For informational and educational purposes only, not investment advice.